Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Exelixis, GlaxoSmithKline deal

GSK exercised an option to license exclusive rights to develop and commercialize EXEL's XL880 under

Read the full 152 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE